However, significant variations in the long-term survival outcomes of patients following SLT have been observed among patients meeting the Milan criteria across regions such as Asia and Europe; furthermore, these variations have been recorded in subgroups based on the timing of tumor recurrence, the levels of alpha-fetoprotein, and the status of liver injury (15–17). This evidence concerns the gene AFP and neoplasm.